Literature DB >> 782809

[Reducing the risks in the treatment of gout and hyperuricaemia (author's transl)].

D P Mertz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 782809     DOI： 10.1055/s-0028-1104258

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN： 0012-0472            Impact factor:   0.628


× No keyword cloud information.
  3 in total

1.  Does benzbromarone in therapeutic doses raise renal excretion of oxipurinol?

Authors:  D P Mertz; R Eichhorn
Journal:  Klin Wochenschr       Date:  1984-12-17

2.  The effect of benzbromarone on allopurinol/oxypurinol kinetics in patients with gout.

Authors:  F O Müller; R Schall; G Groenewoud; H K Hundt; J C van der Merwe; M van Dyk
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 3.  A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?

Authors:  Ming-Han H Lee; Garry G Graham; Kenneth M Williams; Richard O Day
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.